HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

8-bromoguanosine

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Guanosine: 1156
        8-bromoguanosine: 7
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Guanosine: 1156
      - 8-bromoguanosine: 7
  - Ribonucleosides: 49
    - Guanosine: 1156
      - 8-bromoguanosine: 7

Experts

1.	Benny, Jonathan: 1 article (01/2022)
2.	Liu, Jianbo: 1 article (01/2022)
3.	Moe, May Myat: 1 article (01/2022)
4.	Saito, Toru: 1 article (01/2022)
5.	Buzatto, Adriana Zardini: 1 article (05/2017)
6.	Poppi, Ronei Jesus: 1 article (05/2017)
7.	Simionato, Ana Valéria Colnaghi: 1 article (05/2017)
8.	de Oliveira Silva, Mariana: 1 article (05/2017)
9.	Keefer, Larry K: 1 article (02/2011)
10.	Oldfield, Edward H: 1 article (02/2011)

Related Diseases

1.	Cutaneous Leishmaniasis 07/01/2003 - "Efficacy of 8-bromoguanosine against murine cutaneous leishmaniasis induced with Leishmania amazonensis." 07/01/2003 - "In this study, we investigated the effect of 8-bromoguanosine (8Brguo), an immunostimulatory compound, in a murine model of experimental cutaneous leishmaniasis. "
2.	Prostatic Neoplasms (Prostate Cancer) 05/01/2017 - "Graphical Abstract Separation of the studied nucleosides and the internal standard 8-Bromoguanosine by CE-UV (a); classification of the external validation samples (30 from healthy volunteers and 21 from prostate cancer patients) by the developed Partial Least Square - Discriminant Analysis (PLS-DA) model with accuracy of 82.4% (b); Receiver Operating Characteristics (ROC) curve (c); and Variable Importance in the Projection (VIP) values for the studied nucleosides (d). "
3.	Pain (Aches) 03/16/1995 - "The involvement of spinal cord nitric oxide (NO) in the development of autotomy, a proposed behavioral model of denervation pain, was studied in sciatic and saphenous nerves transected rats injected intrathecally, 10-15 min prior to neurectomies, with NG-nitro-L-arginine methyl ester (L-NAME, 20-500 nmol), NG-nitro-D-arginine methyl ester (D-NAME, 500 nmol), L- or D-arginine (5 mumol), and 8-bromoguanosine 3':5'-cyclic monophosphate sodium salt (8-Br-cGMP, 100 and 200 nmol). "
4.	Neoplasms (Cancer) 02/01/2011 - "This effect was achieved without significant changes in cerebral and tumor blood flow or arterial blood pressure, which indicates that the effect on vascular permeability is independent of changes in vascular tone induced by NO. This effect was mediated by activation of the NO/3',5'-cyclic guanosine monophosphate (cGMP) pathway, as it was blocked by guanylate cyclase inhibition by LY83583 and reproduced by the delivery of 8-bromoguanosine 5'-monophosphate or inhibition of cGMP degradation by the phosphodiesterase inhibitor zaprinast. "
5.	Ischemia 01/01/1999 - "Using an experimental model of porcine liver ischemia, 8-bromoguanosine 3',5' monophosphate, a cGMP analog, was continuously administered into the portal vein before ischemia and after reperfusion 30 min for each in the cGMP group (n = 6). "

Related Drugs and Biologics

1.	NG-Nitroarginine Methyl Ester (L-NAME)
2.	Biomarkers (Surrogate Marker)
3.	Sodium
4.	Salts
5.	Phosphodiesterase Inhibitors
6.	Nucleosides
7.	Nitric Oxide (Nitrogen Monoxide)
8.	Guanylate Cyclase (Guanylyl Cyclase)
9.	Guanosine Monophosphate (5' Guanylic Acid)
10.	Arginine (L-Arginine)

Related Therapies and Procedures

1.	Denervation